Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Carter BZ, et al. Among authors: morrow pk. Blood Cancer J. 2023 Apr 24;13(1):57. doi: 10.1038/s41408-023-00830-w. Blood Cancer J. 2023. PMID: 37088806 Free PMC article.
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Carter BZ, et al. Among authors: morrow pk. Blood Cancer J. 2023 May 17;13(1):80. doi: 10.1038/s41408-023-00857-z. Blood Cancer J. 2023. PMID: 37193700 Free PMC article. No abstract available.
Exagamglogene Autotemcel for Severe Sickle Cell Disease.
Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, Wall D, Liem RI, Telfer P, Shah AJ, Cavazzana M, Corbacioglu S, Rondelli D, Meisel R, Dedeken L, Lobitz S, de Montalembert M, Steinberg MH, Walters MC, Eckrich MJ, Imren S, Bower L, Simard C, Zhou W, Xuan F, Morrow PK, Hobbs WE, Grupp SA; CLIMB SCD-121 Study Group. Frangoul H, et al. Among authors: morrow pk. N Engl J Med. 2024 May 9;390(18):1649-1662. doi: 10.1056/NEJMoa2309676. Epub 2024 Apr 24. N Engl J Med. 2024. PMID: 38661449 Clinical Trial.
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.
Locatelli F, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM, de la Fuente J, Shah AJ, Carpenter B, Kwiatkowski JL, Mapara M, Liem RI, Cappellini MD, Algeri M, Kattamis A, Sheth S, Grupp S, Handgretinger R, Kohli P, Shi D, Ross L, Bobruff Y, Simard C, Zhang L, Morrow PK, Hobbs WE, Frangoul H; CLIMB THAL-111 Study Group. Locatelli F, et al. Among authors: morrow pk. N Engl J Med. 2024 May 9;390(18):1663-1676. doi: 10.1056/NEJMoa2309673. Epub 2024 Apr 24. N Engl J Med. 2024. PMID: 38657265 Clinical Trial.
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
Pal SK, Tran B, Haanen JBAG, Hurwitz ME, Sacher A, Tannir NM, Budde LE, Harrison SJ, Klobuch S, Patel SS, Meza L, Dequeant ML, Ma A, He QA, Williams LM, Keegan A, Gurary EB, Dar H, Karnik S, Guo C, Heath H, Yuen RR, Morrow PK, Agarwal N, Srour SA. Pal SK, et al. Among authors: morrow pk. Cancer Discov. 2024 Jul 1;14(7):1176-1189. doi: 10.1158/2159-8290.CD-24-0102. Cancer Discov. 2024. PMID: 38583184 Free PMC article. Clinical Trial.
Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition.
Li BT, Daly B, Gospodarowicz M, Bertagnolli MM, Brawley OW, Chabner BA, Fashoyin-Aje L, de Claro RA, Franklin E, Mills J, Legos J, Kaucic K, Li M, The L, Hou T, Wu TH, Albrecht B, Shao Y, Finnegan J, Qian J, Shahidi J, Gasal E, Tendler C, Kim G, Yan J, Morrow PK, Fuchs CS, Zhang L, LaCaze R, Oelrich S, Murphy MJ, Pazdur R, Rudd K, Wu YL. Li BT, et al. Among authors: morrow pk. Nat Med. 2022 Apr;28(4):620-626. doi: 10.1038/s41591-022-01775-6. Nat Med. 2022. PMID: 35440725 No abstract available.
Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells.
Carter BZ, Mak PY, Tao W, Zhang Q, Ruvolo V, Kuruvilla VM, Wang X, Mak DH, Battula VL, Konopleva M, Jabbour EJ, Hughes PE, Chen X, Morrow PK, Andreeff M. Carter BZ, et al. Among authors: morrow pk. Mol Cancer Ther. 2022 Jun 1;21(6):879-889. doi: 10.1158/1535-7163.MCT-21-0690. Mol Cancer Ther. 2022. PMID: 35364607 Free PMC article.
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.
Stewart MD, McCall B, Pasquini M, Yang AS, Britten CD, Chuk M, De Claro RA, George B, Gormley N, Horowitz MM, Kowack E, McCoy C, Morrow PK, Okoye E, Ricafort R, Rossi J, Sharon E, Theoret M, Vegni F, Yu T, Allen J. Stewart MD, et al. Among authors: morrow pk. Cytotherapy. 2022 Jul;24(7):742-749. doi: 10.1016/j.jcyt.2022.01.004. Epub 2022 Feb 23. Cytotherapy. 2022. PMID: 35219582 Free PMC article.
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
O'Donnell PH, Trubetskoy V, Nurhussein-Patterson A, Hall JP, Nath A, Huo D, Fleming GF, Ingle JN, Abramson VG, Morrow PK, Storniolo AM, Forero A, Van Poznak C, Liu MC, Chang JC, Merkel DE, Peppercorn JM, Rugo HS, Dees EC, Hahn OM, Hoffman PC, Rosner GL, Huang RS, Ratain MJ, Cox N, Olopade OI, Wolff AC, Dolan ME, Nanda R; Translational Breast Cancer Research Consortium (TBCRC). O'Donnell PH, et al. Among authors: morrow pk. Breast Cancer Res Treat. 2020 Jun;181(3):623-633. doi: 10.1007/s10549-020-05603-8. Epub 2020 May 6. Breast Cancer Res Treat. 2020. PMID: 32378051
53 results